EMA accepts Pfizer ’s bosulif Type II Variation application for Ph+ CML
The European Medicines Agency (EMA) has approved for review a Type II Variation application for the use of Pfizer ’s bosulif (bosutinib) to treat patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | European Medicines Agency (EMA) | Leukemia | Pfizer